Finch raises $53 million for microbiome capsule for C. diff

Finch Therapeutics has raised $53 million in Series C financing to support the clinical development of its microbial therapies, including CP101, an oral microbiome capsule for recurrent Clostridioides difficile infection.
The capsule — known as a Full-Spectrum Microbiota therapy — is currently being tested in the company’s PRISM3 trial for the prevention of CDI. The FDA granted Fast Track designation to CP101 last year and a breakthrough designation early in 2019.
According to a press release issued by the company, Finch hopes to expand its microbiome therapies to inflammatory

Source link

Related posts

Low Risk of Peritoneal Seeding from EUS-Guided FNA in Pancreatic Cancer


Open data informatics and data repurposing for IBD


Endoscopic Duodenum Resurfacing Improves Glycemia in T2D


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy